Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius Medical Care AG & Co. KGaA    FME   DE0005785802

FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius Medical Care AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

share with twitter share with LinkedIn share with facebook
03/20/2020 | 11:20am EDT

DGAP Voting Rights Announcement: Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

20.03.2020 / 16:17
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Notification of Major Holdings

1. Details of issuer
Name: Fresenius Medical Care AG & Co. KGaA
Street: Else-Kröner-Straße 1
Postal code: 61352
City: Bad Homburg
Germany
Legal Entity Identifier (LEI): 549300CP8NY40UP89Q40

2. Reason for notification
X Acquisition/disposal of shares with voting rights
  Acquisition/disposal of instruments
  Change of breakdown of voting rights
  Other reason:

3. Details of person subject to the notification obligation
Legal entity: Artisan Partners Asset Management Inc.
City of registered office, country: Wilmington, Delaware, United States of America (USA)

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
 

5. Date on which threshold was crossed or reached:
13 March 2020

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
Total of both in %
(7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New 3.06 % 0.00 % 3.06 % 304439406
Previous notification n/a % n/a % n/a % /

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN Absolute In %
  Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
DE0005785802 0 9309206 0 % 3.06 %
Total 9309206 3.06 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
%
    Total %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
%
      Total %

8. Information in relation to the person subject to the notification obligation
  Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least 3% or more) % of voting rights through instruments (if at least 5% or more) Total of both (if at least 5% or more)
Artisan Partners Asset Management Inc. % % %
Artisan Partners Holdings LP % % %
Artisan Investments GP LLC % % %
Artisan Partners Limited Partnership 3.06 % % %

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights Proportion of instruments Total of both
% % %

10. Other explanatory remarks:
 

Date
17 March 2020



20.03.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Fresenius Medical Care AG & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Internet: www.freseniusmedicalcare.com

 
End of News DGAP News Service

1003439  20.03.2020 

fncls.ssp?fn=show_t_gif&application_id=1003439&application_name=news&site_id=zonebourse
© EQS 2020

share with twitter share with LinkedIn share with facebook
All news about FRESENIUS MEDICAL CARE AG & CO. KGAA
03:57aFMC FRESENIUS MEDICAL CARE AG & CO K : JP Morgan remains its Buy rating
MD
10/29FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 50 of the Wp..
EQ
10/29FRESENIUS SE : Berenberg maintains a Buy rating
MD
10/29FMC FRESENIUS MEDICAL CARE AG & CO K : Berenberg reiterates its Buy rating
MD
10/29FMC FRESENIUS MEDICAL CARE AG & CO K : Receives a Buy rating from UBS
MD
10/29FMC FRESENIUS MEDICAL CARE AG & CO K : Warburg Research sticks Neutral
MD
10/29FRESENIUS SE : Warburg Research remains its Buy rating
MD
10/29FRESENIUS SE : Barclays keeps its Buy rating
MD
10/29FRESENIUS SE : Goldman Sachs remains its Buy rating
MD
10/29FMC FRESENIUS MEDICAL CARE AG & CO K : Kepler Cheuvreux remains its Buy rating
MD
More news
Financials (USD)
Sales 2020 21 200 M - -
Net income 2020 1 543 M - -
Net Debt 2020 13 866 M - -
P/E ratio 2020 14,8x
Yield 2020 1,74%
Capitalization 22 634 M 22 604 M -
EV / Sales 2020 1,72x
EV / Sales 2021 1,59x
Nbr of Employees 124 736
Free-Float 65,1%
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 96,13 $
Last Close Price 77,29 $
Spread / Highest target 48,5%
Spread / Average Target 24,4%
Spread / Lowest Target -17,7%
EPS Revisions
Managers
NameTitle
Rice Powell Chairman-Management Board
Dieter Schenk Chairman-Supervisory Board
Helen Giza Chief Financial Officer
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer
Sector and Competitors